We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+20.67%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.1B
AUM Growth
+$302M
(+17%)
Cap. Flow
+$69.4M
Cap. Flow
% of AUM
3.31%
Top 10 Holdings %
Top 10 Hldgs %
39.8%
Holding
89
New
37
Increased
12
Reduced
15
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$75.2M |
| 2 |
AET
Aetna Inc
AET
|
+$68.6M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$55.8M |
| 4 |
Brookdale Senior Living
BKD
|
+$51.1M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$50.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$120M |
| 2 |
Bausch Health
BHC
|
+$93M |
| 3 |
Pfizer
PFE
|
+$76.9M |
| 4 |
Keysight
KEYS
|
+$69M |
| 5 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$60.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.75% |
| 2 | Financials | 3.56% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCR
26
DELISTED
CR Bard Inc.
BCR
| $33.5M | 1.6% |
+200,000
| New | +$34.3M |
|
27
Vertex Pharmaceuticals
VRTX
$121B
| $32.4M | 1.55% |
+275,000
| New | +$32.9M |
|
|
28
Pfizer
PFE
$143B
| $32.1M | 1.53% |
973,053
-2,419,878
| -71% | -$76.9M |
|
|
RLYP
29
DELISTED
RELYPSA INC COM
RLYP
| $31.6M | 1.51% |
+875,000
| New | +$31.6M |
|
|
AVNS
30
DELISTED
Avanos Medical
AVNS
| $30.5M | 1.46% |
620,800
-330,000
| -35% | -$15.3M |
|
31
CALL
Merck
MRK
$322B
| $28.7M | 1.37% |
+524,000
| New | +$29.7M |
|
|
TSRO
32
PUT
DELISTED
TESARO, Inc.
TSRO
| $28.7M | 1.37% |
+500,000
| New | +$23.6M |
|
|
PDCO
33
DELISTED
Patterson Companies, Inc.
PDCO
| $27.8M | 1.33% |
+570,000
| New | +$28.4M |
|
34
Universal Health Services
UHS
$10.2B
| $26.5M | 1.26% |
225,000
-225,000
| -50% | -$24.9M |
|
35
Acadia Pharmaceuticals
ACAD
$4.43B
| $23.6M | 1.13% |
+725,000
| New | +$24.9M |
|
|
AMRI
36
DELISTED
Albany Molecular Research Inc
AMRI
| $22.4M | 1.07% |
1,275,000
-325,000
| -20% | -$5.54M |
|
37
Agilent Technologies
A
$39.1B
| $21.8M | 1.04% |
525,000
+285,500
| +119% | +$11.5M |
|
|
KYTH
38
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| $21.3M | 1.02% |
425,000
+333,400
| +364% | +$14M |
|
|
TTPH
39
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $17.1M | 0.82% |
+23,360
| New | +$17.5M |
|
40
PUT
Cencora
COR
$60.6B
| $17.1M | 0.81% |
+150,000
| New | +$15.1M |
|
|
ARAV
41
DELISTED
Aravive, Inc. Common Stock
ARAV
| $16.9M | 0.8% |
152,933
+7,100
| +5% | +$833K |
|
42
Arbutus Biopharma
ABUS
$857M
| $12.6M | 0.6% |
+718,800
| New | +$14.7M |
|
|
AERI
43
DELISTED
Aerie Pharmaceuticals
AERI
| $11M | 0.52% |
+350,000
| New | +$10.1M |
|
44
CALL
Tenet Healthcare
THC
$20.5B
| $10.9M | 0.52% |
+220,000
| New | +$10.3M |
|
|
45
PUT
Tenet Healthcare
THC
$20.5B
| $10.9M | 0.52% |
+220,000
| New | +$10.3M |
|
46
Integra LifeSciences
IART
$1.29B
| $10.8M | 0.51% |
+428,133
| New | +$10.1M |
|
|
ELGX
47
DELISTED
Endologix Inc
ELGX
| $9.83M | 0.47% |
+57,580
| New | +$8.72M |
|
48
Thermo Fisher Scientific
TMO
$213B
| $9.15M | 0.44% |
68,100
-331,900
| -83% | -$42.8M |
|
|
DYAX
49
DELISTED
DYAX CORPORATION
DYAX
| $8.21M | 0.39% |
+489,900
| New | +$7.63M |
|
|
DSCI
50
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $7.57M | 0.36% |
893,600
-26,400
| -3% | -$225K |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2015 Portfolio in Review
As of Q1 2015, HealthCor Management held 89 positions worth $2.1B, up 17% from $1.79B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
HealthCor Management deployed $69.4M of net new capital in Q1 2015, opening 37 new positions and adding to 12 existing holdings. Its largest new stake was Biogen: 190,700 shares worth $80.5M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 72% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Gilead Sciences, an estimated $120M trimmed.
- HealthCor Management's largest Q1 2015 buy was Biogen: 190,700 shares worth $80.5M.
- HealthCor Management added most to Brookdale Senior Living in Q1 2015, an estimated $51.1M increase.
- HealthCor Management's biggest Q1 2015 reduction was Gilead Sciences, cutting an estimated $120M.
- HealthCor Management fully exited Bausch Health in Q1 2015, selling an estimated $93M.
- HealthCor Management's ten largest holdings make up 40% of its $2.1B portfolio in Q1 2015.
- HealthCor Management opened 37 new positions and closed 24 in Q1 2015.
- HealthCor Management's portfolio value rose 17% quarter-over-quarter to $2.1B.
Based on HealthCor Management's 13F filing for Q1 2015, filed 15 May 2015.